[Skip to Navigation]
July 25, 1959


Author Affiliations


Professor and Head of Department of Ophthalmology, Graduate School of Medicine of the University of Pennsylvania, and Attending Surgeon and Director of Research, Wills Eye Hospital.

JAMA. 1959;170(13):1547-1550. doi:10.1001/jama.1959.63010130005013

Since the advent of cortisone approximately a decade ago, numerous steroids and steroid derivatives have been evaluated for their ocular effects when administered locally and systemically. These include cortisone (Cortisone, Cortogen, Cortone) acetate and free alcohol, hydrocortisone (Cortef, Cortril, Hycortole, Hydrocortone) acetate and free alcohol, hydrocortisone tertiary-butylacetate, prednisolone (Delta Cortef, Hydeltra, Meticortelone, Meti-Derm, Paracortol) free alcohol and acetate, prednisolone butylacetate (Hydeltra-T. B. A.), methylprednisolone (Medrol), triamcinolone (Aristocort, Kenacort), and dexamethasone (Decadron, Deronil). Not all of these have had completely adequate trial in ophthalmology. However, when topically applied, only minor differences in clinical activity have been noted. If employed in individual dosages and proper vehicles and method of administration, all have equivalent anti-inflammatory potency for ocular diseases. For ophthalmic therapy, these agents may be applied locally in solution or ointment vehicles or injected subconjunctivally. There appears to be no significant advantage to intracameral injection. They may also be used systemically. Corticotropin